Intellia Therapeutics Stock (NTLA:NSD) Analysis:
Last Closing Price: $51.46
Consensus Analyst Rating: Strong Buy
12-Month Price Target: $102.78
Market CAP: $3.79 Billion
Intellia Therapeutics (NTLA:NSD) has set the pricing for its underwritten public offering of 6,550,219 shares of common stock at $45.80 per share.
Before deducting underwriting discounts and commissions and offering expenses, the gross proceeds from the offering are anticipated to be approximately $300 million.
The underwriter has a 30-day option to purchase up to 982,532 more shares of the common Intellia Therapeutics stock.
It is anticipated that the offering would close on or around December 2, 2022.
The market is down 3.81 percent after hours.
NTLA Stock-Analyst Ratings:
Chardan Capital maintains the “Buy” rating with $129 Intellia Therapeutics stock price target.
EF Hutton maintains the “Buy” rating with $123 ntellia Therapeutics stock price target.
About Intellia Therapeutics (NTLA:NSD):
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.
In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.
The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
